Accord Healthcare resumes production of cancer drug cisplatin amid shortages

(Reuters) – The U.S. Meals and Drug Administration (FDA) mentioned on Monday that Accord Healthcare has resumed manufacturing of generally used most cancers drug cisplatin in opposition to the backdrop of ongoing drug shortages in the USA.

Cisplatin is a sort of chemotherapy drug used alone or together with different medication to deal with a number of superior types of most cancers, together with bladder, ovarian and testicular most cancers.

The FDA final week had reported on its web site that Accord resumed manufacturing of one other most cancers drug methotrexate.

Some most cancers medication have been hard-hit by ongoing shortages in the USA, prompting medical doctors to ration medication and complicating therapy plans for sufferers.

Earlier this yr, the well being regulator had signed off on permitting cisplatin made by China’s Qilu Pharmaceutical to be offered within the U.S. The FDA had additionally mentioned it was on the lookout for further suppliers for most cancers medication cisplatin, carboplatin and methotrexate.

Accord Healthcare, a unit of India-based Intas Prescribed drugs, didn’t instantly reply to Reuters’ request for a remark.

The resumption of cisplatin manufacturing was first reported by Bloomberg Information on Monday.

(Reporting by Bhanvi Satija in Bengaluru; Enhancing by Shilpi Majumdar)

Check Also

Adult, teen sent to hospital after shots fired at car by unknown suspects

Jacksonville Sheriff’s Workplace responded to photographs fired at a automobile round 4:30 p.m. Saturday at …

Leave a Reply

Your email address will not be published. Required fields are marked *